Comparative study of the improvement effect of switching from fenofibrate to bezafibrate on lipid and glucose metabolism - Differences in effects between bezafibrate and fenofibrate in clinical practice

Therapeutic Research

Volumn 33, Issue 10, 2012, Pages 1561-1568

  Goto, Toshiaki ^a   Yoshioka, Shuko ^a   Suzuki, Aya ^a   Matsumoto, Shigeru ^a   Fukatsu, Masahiro ^a   Yamada, Tetsuya ^a   Nakamura, Naohito ^a   Mizuno, Naoaki ^a   Sugiyama, Mariko ^a   Shinohara, Yuri ^a   Sato, Ikuko ^a   Takami, Shigehiro ^a  

^a TOSEI GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84869858921     PISSN: 02898020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997;46:1354-9. (Pubitemid 27315286)
2. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
3. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
4. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012-22.
5. Desvergne B, Wahli W. Peroxisome proliferator-activated receptor nuclear control of metabolism. Endocr Rev 1999;20:649-88. (Pubitemid 30650602)
6. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50. (Pubitemid 30127149)
7. Smud R, Sermukslis B. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia. Curr Med Res Opin 1987;10:612-24. (Pubitemid 18045747)
8. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012;3:39-40.
9. Sone H, Tanaka S, Tanaka S, Iimuro S, Ishibashi S, Oikawa S, et al Japan Diabetes Complications Study Group. Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study. Diabetes Care 2012;35:1150-7.
10. Tseng CL, Brimacombe M, Xie M, Rajan M, Wang H, Kolassa J, et al. Seasonal patterns in monthly hemoglobin A1c values. Am J Epidemiol 2005;161:565-74. (Pubitemid 40349912)
11. Sakura H, Tanaka Y, Iwamoto Y. Seasonal fluctuations of glycated hemoglobin levels in Japanese diabetic patients. Diabetes Res Clin Pract 2010;88:65-70.
12. Hossain MA, Tsujita M, Gonzalez FJ, Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J Cardiovasc Pharmacol 2008;51:258-66. (Pubitemid 351450604)
13. Ishikawa M, Namiki A, Kubota T, Yajima S, Fukazawa M, Moroi M, et al. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med 2006;45:51-5. (Pubitemid 43285889)
14. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4) : implications in glycemic control. Diabe tologia 2006;49:1881-92. (Pubitemid 44025043)
15. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004;109:2197-202. (Pubitemid 38656105)
16. Tremblay-Mercier J, Tessier D, Plourde M, Fortier M, Lorrain D, Cunnane SC. Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects. J Pharmacol Exp Ther 2010;334:341-6.
17. Tenenbaum H, Behar S, Boyko V, Adler Y, Fisman EZ, Tanne D, et al. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007;194:265-71. (Pubitemid 47495923)
18. Fujiwara M. Effect of bezafibrate in patients with diabetes and abnormalities of lipid metabolism. Ther Res 2011;32:1317-24.
19. Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol 2012;11:29.
20. Flory JH, Ellenberg S, Szapary PO, Strom BL, Hennessy S. Antidiabetic action of bezafibrate in a large observational database. Diabetes Care 2009;32:547-51.
21. Uetake D, Ohno I, Ichida K, Yamaguchi Y, Saikawa H, Endou H, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010;49:89-94.